-+ 0.00%
-+ 0.00%
-+ 0.00%

CorMedix Publishes Q3 2026 Earnings and Corporate Update Call Transcript

PUBT·11/16/2026 11:13:15
Listen to the news
CorMedix Publishes Q3 2026 Earnings and Corporate Update Call Transcript
  • CorMedix held its third-quarter 2026 earnings call with CEO Joseph Todisco, CFO Susan Blum and Chief Operating and Commercial Officer Liz Hurlburt.
  • Management deferred 2027 DefenCath revenue guidance until early 2027 pending clarity on customer pricing, utilization and Medicare Advantage contracts.
  • The Heron asset acquisition is expected to close in the first quarter of 2027, contributing $125 million–$150 million in revenue that year.
  • Full-year 2026 adjusted EBITDA guidance narrowed to $130 million–$140 million; revenue guidance remained $325 million–$345 million.
  • Quarterly revenue fell to $54.5 million from $104.3 million a year earlier, primarily reflecting lower DefenCath pricing following its reimbursement transition.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-120016), on November 16, 2026, and is solely responsible for the information contained therein.